Obesity Clinical Trial
Official title:
The Childhood Health and Asthma Management Program
Overweight and obese (OV/OB) children with asthma are at-risk for particularly poor health
outcomes including poor asthma control, higher risk of asthma-related symptoms, and
decreased quality of life. Weight loss reduces asthma symptoms, improves lung function, and
increases quality of life among OV/OB adults with asthma. Little research has examined the
impact of weight loss on asthma outcomes in OV/OB youth, and there is little research
examining weight management interventions in OV/OB children with asthma. Behavioral
family-based lifestyle interventions are successful in producing weight loss in children. To
our knowledge, however, there has been no systematic effort to examine the impact of these
interventions on weight status and asthma outcomes, nor has there been an effort to tailor
these programs to the specific needs of OV/OB children with asthma.
The aims of this study are to develop and test the Childhood Health and Asthma Management
Program (CHAMP), a behavioral family-based lifestyle intervention that is community-based to
promote successful weight and asthma management in OV/OB children with asthma. The
investigators propose to develop an intervention based on a previously developed behavioral
family-based lifestyle intervention that was community-based and produced positive long term
weight status changes in OV/OB children and tailor it for OV/OB children with asthma to
create CHAMP. CHAMP will include asthma education and targeting unique barriers to weight
management in OV/OB children with asthma. A focus group will be conducted with OV/OB
children with asthma, ages 6-12, and their parent(s). Then a pilot randomized controlled
trial of the CHAMP intervention with 32 OV/OB children with asthma, ages 6-12 years, and
their parent(s). Families will be randomly assigned to CHAMP or a health education group.
The investigators hypothesize that participants in CHAMP will have more effective weight and
asthma management and child asthma outcomes compared to those in the general education
group.
At the first appointment the following information will be collected to determine
eligibility for the research study. If participation is determined, a second visit will be
scheduled at the end of the visit or the potential participant will be provided with a
suggestion to speak with their primary care physician for other treatment options.
A measurement of height and weight will be taken, questionnaires regarding medical history,
including asthma symptoms and control, and questionnaires about family background
information (e.g., family income, size of family, employment, and marital status).
In addition, information concerning the following conditions will be collected and may
exclude participation: dietary restriction or a medical condition that makes mild energy
restriction or physical activity potentially dangerous, diagnosed with a major psychiatric
disorder such as schizophrenia, bipolar disorder or autism, has used systemic
corticosteroids within 3 months, or prescription weight loss drugs within 6 months.
The second appointment will happen one to two weeks before the start of the treatment
program. During this visit the following will happen:
A measurement of height and weight, and waistline, questionnaires and complete an interview
about asthma management and quality of life, and a test for lung function both pre and post
albuterol. At the end of the visit an accelerometer will be provided to wear for 7 days in a
row. The accelerometer will measure how much exercise is done each day.
At the end of this visit, the participant will be randomly assignment to either the
experimental Childhood Health and Asthma Management Program (CHAMP) group or the health
education group.
The CHAMP group will receive tailored asthma education and behavioral skills focused on
improving asthma and weight management.
The health education group will receive tailored asthma education and general health
education on a variety of topics.
Each of the treatment programs will last for 6 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |